FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 797 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Research with integrity – the importance of communication November 14, 2022 Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age October 26, 2020 FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection February 7, 2025 Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... February 17, 2023 Load more HOT NEWS Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... New on NCI’s Websites for December 2023 FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell... Cancer Research UK releases 2022 gender and ethnicity pay gap reports
